71 results on '"Yonemori, K"'
Search Results
2. Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer
3. FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
4. Compliance with Good Clinical Practice in oncology registration trials in Japan
5. Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy
6. Participation of elderly patients in registration trials for oncology drug applications in Japan
7. 383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study
8. 405P E7389-LF as a first-line (1L) chemotherapy for patients (pts) with metastatic/advanced HER2-negative breast cancer (HER2− BC): Results from a phase I study dose-expansion part
9. LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
10. 1722P Factors contributing to differences in evidence compliance rate in cancer treatment among second opinion cases
11. 786P Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
12. 748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
13. P-126 TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer
14. Diagnostic accuracy of CT-guided percutaneous cutting needle biopsy for thymic tumours
15. 244 (PB024) - Phase I Biomarker Analysis Results of MORAb-202 (Farletuzumab Ecteribulin) Effects on Vascular Remodeling and Immune Modulation in Patients With Ovarian Cancer
16. 1523P Incidence and geographic distribution of bone and soft tissue sarcoma in Japan using a nationwide population-based analysis: 69,734 cases
17. 1633P The correlation between the geographical distribution of asbestos-exposed workplaces and the increased risk of developing malignant mesothelioma, lung cancer, laryngeal cancer, and ovarian cancer: A nationwide population-based analysis in Japan
18. 525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
19. 264P Increased membrane HER3 expression in brain metastases compared to primary tumors in breast cancer
20. 173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2
21. 160TiP A randomized controlled phase III study of bevacizumab and paclitaxel in combination with atezolizumab as a treatment for patients with locally advanced or metastatic hormone receptor-positive HER2-negative breast cancer: JCOG1919E/AMBITION study
22. 1767P Co-clinical PDX study of trastuzumab deruxtecan in HER2-positive uterine carcinosarcoma (STATICE trial, NCCH1615)
23. 980P Phase Ib study of a liposomal formulation of eribulin (E7389-LF) + nivolumab (Nivo) in patients (pts) with advanced solid tumors
24. 813P Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): A multicenter, phase II clinical trial
25. 1521O A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004)
26. 171P Combining tumor-infiltrating lymphocytes and PD-L1 expression can stratify prognosis in early-stage triple-negative breast cancer patients who did not receive adjuvant chemotherapy
27. 245P Clinicopathological features including response to platinum-based chemotherapy in endometrial carcinomas involving SWI/SNF complex inactivation
28. 236O Olaparib (ola) plus bevacizumab (bev) as maintenance (mx) therapy in patients (pts) with newly diagnosed advanced ovarian carcinoma (OC): Japan subset of the PAOLA-1 trial
29. Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial
30. LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial
31. 534MO First in human study of ONO-4578, a PGE2-receptor EP4 antagonist, in monotherapy and combination with PD-1 checkpoint inhibitor nivolumab in patients with advanced or metastatic solid tumours
32. 17O A first-in-human phase I study of MORAb-202 in patients with folate receptor alpha-positive advanced solid tumors
33. 1732TiP - A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
34. 456P - First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours
35. 441O - A platform trial with a registry study for rare cancers: MASTER KEY project
36. 348P - Phase I study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumours: Primary results of dose-escalation part
37. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
38. 409P - Prognostic factors for post-progression survival after trabectedin treatment in patients with advanced soft tissue sarcoma
39. 397O - Adolescents and young adults with cancer care in Asia: The joint ESMO/SIOPE/SIOP ASIA survey
40. 449TiP - MASTER KEY project: A basket/umbrella trial for rare cancers in Japan
41. 423P - Phase I study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors
42. 348 (PB-143) - Neoadjuvant eribulin in early triple negative breast cancer
43. 120P - Comparison of model-based dose escalation design with rule-based design of phase I oncology trials
44. 114P - Impact by age on dose-limiting toxicities in phase 1 oncology trials of cytotoxic agents and molecular targeted agents
45. 494P - Eribulin mesylate in patients with soft-tissue sarcoma other than L-sarcoma
46. 578P - Current situation and problems of ‘drug lag’ for oncology drugs in Japan
47. 300P - Outcomes of paclitaxel and ifosfamide following surgery for early and advanced stage uterine carcinosarcoma: A single institution experience
48. 137P - Prognostic factors of patients received immunocheckpoint inhibitors in oncology phase 1 trials
49. 100P - Impact of perioperative fluoropyrimidines on the efficacy of capecitabine in patients with advanced breast cancer: A retrospective study
50. 46P - The frequency of somatic AKT1 mutation among Japanese breast and endometrial cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.